Literature DB >> 12388971

Maternal lymphocyte subpopulations (CD45RA+ and CD45RO+) in preeclampsia.

Tinnakorn Chaiworapongsa1, Maria-Teresa Gervasi, Jerrie Refuerzo, Jimmy Espinoza, Jun Yoshimatsu, Susan Berman, Roberto Romero.   

Abstract

OBJECTIVE: The maternal syndrome of preeclampsia has been attributed to a systemic intravascular inflammatory response and endothelial cell dysfunction. The stimulus responsible for intravascular inflammation in preeclampsia has not been determined. The expression of CD45 isoforms on the surface of human T cells has been used to classify CD4(+) T lymphocytes into naïve cells (CD45RA+) and memory T cells (CD45RO+). An increased percentage of CD45RO+ cells has been interpreted as consistent with previous exposure to microbial products or other antigens. The purpose of this study was to determine whether preeclampsia is associated with a change in the proportion of CD45RA+ and CD45RO+. STUDY
DESIGN: A prospective study was conducted in patients with preeclampsia (n = 24) and normal pregnancy (n = 75). The percentage of CD45RA+ and CD45RO+ on CD4(+) T lymphocytes in peripheral blood was determined using flow cytometry and monoclonal antibodies. Results were reported as a percentage of CD4(+) lymphocytes. Parametric statistics were used for analysis. A probability value of <.05 was considered statistically significant.
RESULTS: Patients with preeclampsia had a significantly higher percentage of CD45RO+ than normal pregnant women (P <.01). A significantly lower percentage of CD45RA+ was found in patients with preeclampsia than in normal pregnant women (P <.01).
CONCLUSION: Preeclampsia is associated with an increase in the percentage of CD45RO+ and a decrease in the CD45RA+ lymphocyte subpopulation. Therefore, patients with preeclampsia have evidence of previous antigenic exposure, the nature of which remains to be established.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388971     DOI: 10.1067/mob.2002.127309

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

1.  The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study.

Authors:  Roberto Romero; Offer Erez; Eli Maymon; Piya Chaemsaithong; Zhonghui Xu; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Done; Sonia S Hassan; Adi L Tarca
Journal:  Am J Obstet Gynecol       Date:  2017-03-03       Impact factor: 8.661

2.  Symptom severity predicts degree of T cell activation in adult women following childhood maltreatment.

Authors:  Andrine Lemieux; Christopher L Coe; Molly Carnes
Journal:  Brain Behav Immun       Date:  2008-04-18       Impact factor: 7.217

3.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

4.  Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods.

Authors:  Daniel B DiGiulio; Mariateresa Gervasi; Roberto Romero; Shali Mazaki-Tovi; Edi Vaisbuch; Juan Pedro Kusanovic; Kimberley S Seok; Ricardo Gómez; Pooja Mittal; Francesca Gotsch; Tinnakorn Chaiworapongsa; Enrique Oyarzún; Chong Jai Kim; David A Relman
Journal:  J Perinat Med       Date:  2010-09       Impact factor: 1.901

5.  The profiles of soluble adhesion molecules in the "great obstetrical syndromes".

Authors:  Nikolina Docheva; Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Gaurav Bhatti; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Tinnakorn Chaiworapongsa; Eli Maymon; Sonia S Hassan; Offer Erez
Journal:  J Matern Fetal Neonatal Med       Date:  2018-02-01

6.  Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Nandor Gabor Than; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Pooja Mittal; Zhong Dong; Tinnakorn Chaiworapongsa; Chong Jai Kim; Chia-Ling Nhan-Chang; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-19

7.  Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?

Authors:  Shali Mazaki-Tovi; Roberto Romero; Sun Kwon Kim; Edi Vaisbuch; Juan Pedro Kusanovic; Offer Erez; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Chia-Ling Nhan-Chang; Nandor Gabor Than; Ricardo Gomez; Jyh Kae Nien; Samuel S Edwin; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-08

8.  Exodus-1 (CCL20): evidence for the participation of this chemokine in spontaneous labor at term, preterm labor, and intrauterine infection.

Authors:  Neil Hamill; Roberto Romero; Francesca Gotsch; Juan Pedro Kusanovic; Sam Edwin; Offer Erez; Nandor Gabor Than; Pooja Mittal; Jimmy Espinoza; Lara A Friel; Edi Vaisbuch; Shali Mazaki-Tovi; Sonia S Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

9.  Severe preeclampsia is characterized by increased placental expression of galectin-1.

Authors:  Nandor Gabor Than; Offer Erez; Derek E Wildman; Adi L Tarca; Samuel S Edwin; Asad Abbas; John Hotra; Juan Pedro Kusanovic; Francesca Gotsch; Sonia S Hassan; Jimmy Espinoza; Zoltan Papp; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2008-07

10.  Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation.

Authors:  Offer Erez; Roberto Romero; Sung-Su Kim; Jung-Sun Kim; Yeon Mee Kim; Derek E Wildman; Nandor Gabor Than; Shali Mazaki-Tovi; Francesca Gotsch; Beth Pineles; Juan Pedro Kusanovic; Jimmy Espinoza; Pooja Mittal; Moshe Mazor; Sonia S Hassan; Chong Jai Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.